hotspot -WSS

hotspot

author：leisure time 2025-09-28 02:27:53 - browse：2364

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Letters to First Opinion on caregivers, digital health, and more

knowledge

hotspot

WSS

Shifting the focus from loneliness to social health

How to protect coverage of PrEP

How to increase colonoscopy rates? Looks like an AI can help

Letters to First Opinion on caregivers, digital health, and more

Intellia reports positive results for its CRISPR

Sophia Smith scores twice for US in in 3

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

New air purifier tech could be key to improving indoor air quality

Cord blood banking comes at a high cost to babies

Trump demands the U.S. pay no more for drugs than other countries … again

At ASCO, AstraZeneca reports strong data for breast cancer drug

Continuity nursing helped my family in our darkest PICU moments

Letters to First Opinion on caregivers, digital health, and more

Bright Health sells Medicare Advantage business to Molina

Sophia Smith scores twice for US in in 3

23andMe had bad news about my health. I wish a person had delivered it

See how much Covid

focus

FDA's Pazdur wants cancer trials to range beyond China alone

Shifting the focus from loneliness to social health

Ionis drug prevents swelling attacks due to hereditary angioedema

Ionis drug prevents swelling attacks due to hereditary angioedema

At ASCO, AstraZeneca reports strong data for breast cancer drug

The Pandemic Treaty must support building strong health systems

explore

knowledge

hotspot

hotspot